Iams Wealth Management LLC Has $1.98 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Iams Wealth Management LLC reduced its holdings in Abbott Laboratories by 12.4% in Q2, now owning 14,540 shares valued at nearly $1.98 million.
• A number of hedge funds, including Vanguard Group Inc. and Goldman Sachs Group Inc., increased their stakes in Abbott during the first quarter, reflecting increased institutional confidence.
• Abbott Laboratories recently declared a quarterly dividend of $0.59 per share, representing an annualized dividend yield of 1.7%.

Iams Wealth Management LLC lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 12.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,540 shares of the healthcare product maker's stock after selling 2,050 shares during the quarter. Iams Wealth Management LLC's holdings in Abbott Laboratories were worth $1,978,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hughes Financial Services LLC bought a new stake in Abbott Laboratories in the 1st quarter valued at $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $30,000. JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $33,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.6%

Shares of NYSE:ABT traded up $0.78 during mid-day trading on Monday, reaching $136.82. The stock had a trading volume of 4,837,007 shares, compared to its average volume of 5,199,671. The firm has a market cap of $238.13 billion, a PE ratio of 17.15, a price-to-earnings-growth ratio of 2.58 and a beta of 0.69. The firm has a 50 day simple moving average of $130.56 and a two-hundred day simple moving average of $131.11. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.

Analysts Set New Price Targets

ABT has been the topic of several analyst reports. Evercore ISI upped their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research report on Friday, July 18th. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Finally, Leerink Partners initiated coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $145.22.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.